APPN Jumps 25.9% on EPS Revision; ALMR, BRCB, REAX, AGIO Also Surge
Appian (APPN) led gains, jumping 25.9% to $48.73 after its next-year EPS growth estimate was revised to 31.3% on October 13, supported by Citi's bullish AI-demand call. Alamar Biosciences (ALMR) rose 24.0% following a 3.8pp upward EPS revision to 49.1%, while Black Rock Coffee Bar (BRCB) gained 19.9% after its estimate ticked up to 30.0%.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| APPN | Technology | 2026-10-13 | N/A | +25.9% |
| ALMR | Healthcare | 2026-10-14 | +3.8pp | +24.0% |
| BRCB | Consumer Cyclical | 2026-10-14 | +1.3pp | +19.9% |
| REAX | Real Estate | 2026-10-14 | +99.0pp | +16.5% |
| AGIO | Healthcare | 2026-10-15 | N/A | +15.0% |
Why did APPN stock jump in October 2026?
APPN jumped 25.9% (from $38.71 to $48.73) after analysts set its next-year EPS growth estimate at 31.3% on October 13.
The screener flagged the revision early, and the market confirmed it as Citi highlighted Appian's accelerating cloud growth and improving federal demand on October 15, maintaining a buy rating. The company's AI automation platform, which has automated critical business processes for over 25 years, positions it to benefit from enterprise demand for AI-driven workflow tools. Appian reports third-quarter 2026 results on November 5, giving investors a near-term catalyst to validate the estimate.
APPN EPS revision history → · Screener snapshot from 2026-10-13 →
FAQ: APPN
Why did APPN stock jump?
APPN jumped 25.9% to $48.73 after its next-year EPS growth estimate was set at 31.3% on October 13, with Citi reinforcing the bullish case on October 15.
Is APPN a buy after the rally?
Citi maintains a buy rating on APPN, citing accelerating cloud growth and improving federal demand, though the stock has already gained 25.9% since the October 13 detection.
What is APPN's EPS growth estimate?
APPN's next-year EPS growth estimate stands at 31.3% as of the October 13 revision.
Why did ALMR stock jump in October 2026?
ALMR rose 24.0% (from $25.37 to $31.45) after its next-year EPS growth estimate was revised up from 45.3% to 49.1% on October 14.
No company-specific news drove the move; the gain reflects the screener catching a 3.8 percentage point upward revision that the market subsequently validated. The healthcare sector's momentum, particularly for companies with strong forward earnings visibility, supported the rally.
ALMR EPS revision history → · Screener snapshot from 2026-10-14 →
FAQ: ALMR
Why did ALMR stock jump?
ALMR jumped 24.0% to $31.45 after its next-year EPS growth estimate was revised up to 49.1% from 45.3% on October 14.
What caused ALMR's surge?
The surge was driven by a 3.8 percentage point upward EPS revision on October 14, with no company-specific news in the window.
What is ALMR's EPS growth estimate?
ALMR's next-year EPS growth estimate is 49.1% following the October 14 revision.
Why did BRCB stock jump in October 2026?
BRCB gained 19.9% (from $7.22 to $8.66) after its next-year EPS growth estimate was revised up from 28.7% to 30.0% on October 14.
The move came without company-specific news, suggesting the screener's early detection of the 1.3 percentage point revision attracted buyers. Consumer cyclical stocks with improving earnings outlooks have seen renewed interest as investors position for a potential soft-landing scenario.
BRCB EPS revision history → · Screener snapshot from 2026-10-14 →
FAQ: BRCB
Why did BRCB stock jump?
BRCB jumped 19.9% to $8.66 after its next-year EPS growth estimate was raised to 30.0% from 28.7% on October 14.
Is BRCB a buy after the rally?
The 19.9% gain since detection reflects market confirmation of the EPS revision, though no analyst commentary was available in the window.
What is BRCB's EPS growth estimate?
BRCB's next-year EPS growth estimate is 30.0% as of the October 14 revision.
Why did REAX stock jump in October 2026?
REAX soared 16.5% (from $13.60 to $15.85) after its next-year EPS growth estimate was revised up dramatically from 195.2% to 294.2% on October 14.
The 99.0 percentage point revision is the largest among today's movers, signaling a major earnings outlook upgrade. The company also announced on October 19 that it will host its third-quarter 2026 earnings conference call, giving investors a near-term opportunity to hear management's perspective on the revised growth trajectory.
REAX EPS revision history → · Screener snapshot from 2026-10-14 →
FAQ: REAX
Why did REAX stock jump?
REAX jumped 16.5% to $15.85 after its next-year EPS growth estimate was revised up to 294.2% from 195.2% on October 14.
What caused REAX's surge?
A 99.0 percentage point upward EPS revision on October 14 drove the surge, with the company also announcing its Q3 earnings call date on October 19.
What is REAX's EPS growth estimate?
REAX's next-year EPS growth estimate is 294.2%, up from 195.2% prior to the October 14 revision.
Why did AGIO stock jump in October 2026?
AGIO climbed 15.0% (from $32.32 to $37.18) after its next-year EPS growth estimate was set at 34.9% on October 15.
No company-specific news was found in the window, indicating the screener's detection of the estimate revision itself was the primary catalyst. The healthcare stock's gain reflects broader sector strength and growing investor confidence in its forward earnings profile.
AGIO EPS revision history → · Screener snapshot from 2026-10-15 →
FAQ: AGIO
Why did AGIO stock jump?
AGIO jumped 15.0% to $37.18 after its next-year EPS growth estimate was set at 34.9% on October 15.
Is AGIO a buy after the rally?
The 15.0% gain since detection reflects market validation of the 34.9% EPS growth estimate, though no analyst commentary was available in the window.
What is AGIO's EPS growth estimate?
AGIO's next-year EPS growth estimate is 34.9% as of the October 15 revision.
Today's performers signal that upward EPS revisions, even without accompanying news, can drive significant price appreciation as the market validates the improved earnings outlook. The concentration in technology and healthcare suggests investors are rewarding forward growth visibility in these sectors.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →